Results 241 to 250 of about 54,330 (287)
Some of the next articles are maybe not open access.
Treatment of Mantle-Cell Lymphoma
New England Journal of Medicine, 2022[No Abstract Available]
Burhan, Ferhanoglu +2 more
openaire +5 more sources
Current Treatment Options in Oncology, 2000
Mantle cell lymphoma is an aggressive non-Hodgkin's lymphoma that remains incurable with current chemotherapeutic approaches. Despite response rates to many regimens of 50% to 70%, the disease typically progresses after chemotherapy with a median survival time of approximately 3 years.
J J, Densmore, M E, Williams
openaire +3 more sources
Mantle cell lymphoma is an aggressive non-Hodgkin's lymphoma that remains incurable with current chemotherapeutic approaches. Despite response rates to many regimens of 50% to 70%, the disease typically progresses after chemotherapy with a median survival time of approximately 3 years.
J J, Densmore, M E, Williams
openaire +3 more sources
Properties of the mantle cell and mantle cell lymphoma
Current Opinion in Hematology, 2002The major lymphoid inhabitant of the follicular mantle is the mantle cell, an immunologically naïve B cell. It is the putative cell of origin of mantle cell lymphoma (MCL), the cells of which have similar morphologic, immunophenotypic, and molecular characteristics to the normal B lymphocytes of the mantle zone.
John L, Frater, Eric D, Hsi
openaire +2 more sources
1997
MCLs are thought to arise from a subset of B cells that normally express the CD5 antigen and that reside in the mantle zone of secondary lymphoid follicles. Although expression of the CD5 antigen is also seen in small lymphocytic lymphoma and chronic lymphocytic leukemia, MCL differs from SLL/ CLL in several ways.
M A, Rodriguez, W C, Pugh
openaire +2 more sources
MCLs are thought to arise from a subset of B cells that normally express the CD5 antigen and that reside in the mantle zone of secondary lymphoid follicles. Although expression of the CD5 antigen is also seen in small lymphocytic lymphoma and chronic lymphocytic leukemia, MCL differs from SLL/ CLL in several ways.
M A, Rodriguez, W C, Pugh
openaire +2 more sources
Bortezomib In Mantle Cell Lymphoma
Future Oncology, 2008Mantle cell lymphoma (MCL) represents 6% of non-Hodgkin lymphomas, but is one of the most active fields of clinical investigation. Unfortunately, there is still no standard or curative therapy in MCL. Front-line therapy appears to benefit from intensification either through high-dose therapy with stem cell transplant consolidation or dose-intense ...
K Stephen, Suh, Andre, Goy
openaire +2 more sources
Mantle-Cell Lymphomas of the Skin
Dermatologic Clinics, 1994The skin lesions of two elderly women lead us to the diagnosis of small cleaved lymphocytic B-cell non-Hodgkin's lymphoma, TNM stage IVb after clinical staging examinations. Relapses occurred within less than 1 year. Morphology, enzymhistochemistry (alkaline phosphatase in the first case), and immunohistochemistry (CD 5 positivity in the second case ...
M L, Geerts, A M, Busschots
openaire +2 more sources
Leukemia & Lymphoma, 2013
Over the past decade, it has become increasingly clear that mantle cell lymphoma (MCL) is a more heterogeneous disease than originally recognized. Several groups have reported on a subgroup of patients with a less aggressive course than expected resulting in the term "indolent MCL".
Eric D, Hsi, Peter, Martin
openaire +2 more sources
Over the past decade, it has become increasingly clear that mantle cell lymphoma (MCL) is a more heterogeneous disease than originally recognized. Several groups have reported on a subgroup of patients with a less aggressive course than expected resulting in the term "indolent MCL".
Eric D, Hsi, Peter, Martin
openaire +2 more sources
Ibrutinib for Mantle Cell Lymphoma
Future Oncology, 2016Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor. Early clinical trials have demonstrated excellent tolerability and a modest side-effect profile in relapsed/refractory MCL.
David L, Tucker, Simon A, Rule
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2020
Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity.
Preetesh, Jain, Michael, Wang
openaire +2 more sources
Blastoid and pleomorphic mantle cell lymphoma (MCL) are among the worst prognostic, aggressive histology, high-risk variants of MCL, and, in this article, they are presented as blastoid MCL. Blastoid MCL have not been systematically studied, probably due to their rarity.
Preetesh, Jain, Michael, Wang
openaire +2 more sources
Lenalidomide for mantle cell lymphoma
Expert Review of Hematology, 2015Mantle cell lymphoma accounts for 6% of all non-Hodgkin lymphomas. It is a biologically and clinically heterogeneous disease and treatment may be difficult, since most patients present at an older age, being unable to undergo intensive chemotherapy. Lenalidomide is an approved medication for relapsed mantle cell lymphoma in patients who received at ...
Alan P, Skarbnik, Andre H, Goy
openaire +2 more sources